Karyopharm Therapeutics Inc.
- KPTI
- NASDAQ
- Biotechnology
- Cancer Therapeutics (Nuclear Export Inhibitors)
$0.39
Today +11.20%Quote Oct 16, 2026, 08:00 PM UTC
−78.21%over the last month
Max drawdown −83.2%From 1-month high −79.3%3 months −94.8%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$8.8M
Quote Oct 16
Next earnings
Nov 2
Expected, not confirmed
Analyst target
$9.50
+2335.3% from here
Floor
$0.28
29.4% below price
Where the price sits
20 analysts
Analyst range, low to high
$3.00$16.00
- Price $0.39
- Resistance $0.42
- Consensus $9.50
Analysts' average target sits about 2335% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about KPTIPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
Q2 2026 revenue $33.4M
- License and Service$1.9M5.7%
- Health Care, Other$77,0000.2%
- Other / not reported$31.5M94.1%
Industry
Biotechnology
Employees
228